These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 34405765)

  • 1. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
    Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
    J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
    Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
    J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SARS-CoV-2 RNA dependent RNA polymerase inhibitors using pharmacophore modelling, molecular docking and molecular dynamics simulation approaches.
    Pundir H; Joshi T; Pant M; Bhat S; Pandey J; Chandra S; Tamta S
    J Biomol Struct Dyn; 2022; 40(24):13366-13377. PubMed ID: 34637693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches.
    Rehman HM; Sajjad M; Ali MA; Gul R; Naveed M; Aslam MS; Shinwari K; Bhinder MA; Ghani MU; Saleem M; Rather MA; Ahmad I; Amin A
    Int J Biol Macromol; 2023 May; 237():124169. PubMed ID: 36990409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19.
    Rafi MO; Bhattacharje G; Al-Khafaji K; Taskin-Tok T; Alfasane MA; Das AK; Parvez MAK; Rahman MS
    J Biomol Struct Dyn; 2022 May; 40(8):3711-3730. PubMed ID: 33251975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.
    Mishra A; Rathore AS
    Mol Divers; 2022 Oct; 26(5):2613-2629. PubMed ID: 35000060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.
    Aouidate A; Ghaleb A; Chtita S; Aarjane M; Ousaa A; Maghat H; Sbai A; Choukrad M; Bouachrine M; Lakhlifi T
    J Biomol Struct Dyn; 2021 Aug; 39(12):4522-4535. PubMed ID: 32552534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual screening and structure-based 3D pharmacophore approach to identify small-molecule inhibitors of SARS-CoV-2 M
    Elseginy SA
    J Biomol Struct Dyn; 2022; 40(24):13658-13674. PubMed ID: 34676801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure-activity relationships, molecular docking and molecular dynamics simulations reveal drug repurposing candidates as potent SARS-CoV-2 main protease inhibitors.
    de Souza AS; de Souza RF; Guzzo CR
    J Biomol Struct Dyn; 2022; 40(21):11339-11356. PubMed ID: 34370631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors.
    Lotfi B; Mebarka O; Khan SU; Htar TT
    J Biomol Struct Dyn; 2024 Jul; 42(10):5308-5320. PubMed ID: 37334701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation.
    Daoud I; Mesli F; Melkemi N; Ghalem S; Salah T
    J Biomol Struct Dyn; 2022; 40(23):12574-12591. PubMed ID: 34541995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of natural inhibitors against prime targets of SARS-CoV-2 using molecular docking, molecular dynamics simulation and MM-PBSA approaches.
    Sharma A; Vora J; Patel D; Sinha S; Jha PC; Shrivastava N
    J Biomol Struct Dyn; 2022 Apr; 40(7):3296-3311. PubMed ID: 33183178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
    Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
    J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential SARS-CoV-2 RdRp inhibitors of cytidine derivatives: Molecular docking, molecular dynamic simulations, ADMET, and POM analyses for the identification of pharmacophore sites.
    M A Kawsar S; Hosen MA; Ahmad S; El Bakri Y; Laaroussi H; Ben Hadda T; Almalki FA; Ozeki Y; Goumri-Said S
    PLoS One; 2022; 17(11):e0273256. PubMed ID: 36441684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight parameter drug design for human β-tryptase inhibition integrated molecular docking, QSAR, molecular dynamics simulation, and pharmacophore modelling studies of α-keto-[1,2,4]-oxadiazoles.
    Yu CX; Tan JW; Rullah K; Imran S; Tham CL
    J Biomol Struct Dyn; 2023; 41(22):12978-12996. PubMed ID: 36709457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
    Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
    Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
    Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C
    J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular docking, pharmacophore modelling, MD simulation and
    Oluyori AP; Olanipekun BE; Adeyemi OS; Egharevba GO; Adegboyega AE; Oladeji OS
    J Biomol Struct Dyn; 2023 Mar; 41(4):1510-1525. PubMed ID: 34996336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore-based virtual screening and
    Roney M; Huq AKMM; Issahaku AR; Soliman MES; Hossain MS; Mustafa AH; Islam MA; Dubey A; Tufail A; Mohd Aluwi MFF; Tajuddin SN
    J Biomol Struct Dyn; 2023; 41(21):12186-12203. PubMed ID: 36645141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.